Cytoplasmic expression of c-erbB2 in non-small cell lung cancers

Virchows Archiv

Volumn 446, Issue 6, 2005, Pages 596-603

  Cheng, Chun Mei ^a   Tsuneyama, Koichi ^a   Matsui, Kazuhiro ^a   Takahashi, Hiroyuki ^a   Ishizawa, Shin ^a   Takano, Yasuo ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

c erbB2; Cytoplasmic expression; Non small cell lung cancers

Indexed keywords

CYTOPLASM PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MEMBRANE PROTEIN; MESSENGER RNA;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER SURGERY; CELL MEMBRANE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CULTURE MEDIUM; CYTOPLASM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MEMBRANE; CYTOPLASM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS;

EID: 21544477528     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-005-1258-7     Document Type: Article

References (24)

1. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J (1998) Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58:2825-2831
2. Beguinot L, Lyall RM, Willingham MC, Pastan I (1984) Down-regulation of the epidermal growth factor receptor in KB cells is due to receptor internalization and subsequent degradation in lysosomes. Proc Natl Acad Sci USA 81:2384-2388
3. Giatromanolaki A, Gorgoulis V, Chetty R, Koukourakis MI, Whitehouse R, Kittas C, Veslemes M, Gatter KC, Iordanoglou I (1996) C-erbB-2 oncoprotein expression in operable non-small cell lung cancer. Anticancer Res 16:987-993
4. Giatromanolaki A, Koukourakis MI, O'Byrne K, Kaklamanis L, Dicoglou C, Trichia E, Whitehouse R, Harris AL, Gatter KC (1996) Non-small cell lung cancer: c-erbB-2 overexpression correlates with low angiogenesis and poor prognosis. Anticancer Res 16:3819-3825
5. Hatanaka Y, Hashizume K, Kamihara Y, Itoh H, Tsuda H, Osamura RY, Tani Y (2001) Quantitative immunohistochemical evaluation of HER2/neu expression with HercepTestTM in breast carcinoma by image analysis. Pathol Int 51:33-36
6. Hirsch FR, Franklin WA, Veve R, Varella-Garcia M, Bunn PA Jr (2002) HER2/neu expression in malignant lung tumors. Semin Oncol 29:51-58
7. Hirsch FR, Varella-Garcia M, Franklin WA, Veve R, Chen L, Helfrich B, Zeng C, Baron A, Bunn PA Jr (2002) Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer 86:1449-1456
8. Ibrahim SO, Lillehaug JR, Johannessen AC, Liavaag PG, Nilsen R, Vasstrand EN (1999) Expression of biomarkers (p53, transforming growth factor alpha, epidermal growth factor receptor, c-erbB-2/neu and the proliferative cell nuclear antigen) in oropharyngeal squamous cell carcinomas. Oral Oncol 35:302-313
9. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ (2001) Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 17:1983-1987
10. Klapper LN, Waterman H, Sela M, Yarden Y (2000) Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res 60: 3384-3388
11. Kristiansen G, Yu Y, Petersen S, Kaufmann O, Schluns K, Dietel M, Petersen I (2001) Overexpression of c-erbB2 protein correlates with disease-stage and chromosomal gain at the c-erbB2 locus in non-small cell lung cancer. Eur J Cancer 37:1089-1095
12. Kumada T, Tsuneyama K, Hatta H, Ishizawa S, Takano Y (2004) Improved one-hour rapid immunostaining method using intermittent microwave irradiation: practicability based on five years application in Toyama Medical and Pharmaceutical University Hospital. Mod Pathol 17:1141-1149
13. Levkowitz G, Oved S, Klapper LN, Harari D, Lavi S, Sela M, Yarden Y (2000) c-Cbl is a suppressor of the neu oncogene. J Biol Chem 275:35532-35539
14. Meert AP, Martin B, Paesmans M, Berghmans T, Mascaux C, Verdebout JM, Delmotte P, Lafitte JJ, Sculier JP (2003) The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. Br J Cancer 89:959-965
15. Murata S, Chiba T, Tanaka K (2003) CHIP: a quality-control E3 ligase collaborating with molecular chaperones. Int J Biochem Cell Biol 35:572-578
16. Piyathilake CJ, Frost AR, Manne U, Weiss H, Bell WC, Heimburger DC, Grizzle WE (2002) Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung. Clin Cancer Res 8:734-744
17. Rao N, Dodge I, Band H (2002) The Cbl family of ubiquitin ligases: critical negative regulators of tyrosine kinase signaling in the immune system. J Leukoc Biol 71:753-763
18. Semba K, Kamata N, Toyoshima K, Yamamoto T (1985) A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA 82:6497-6501
19. Sobin LH, Wittekind C (eds.) (2002) Lung and pleural tumors. In: The TNM Classification of malignant tumours. UICC, International union against cancer. Wiley-Liss, Canada, pp 97-107
20. Travis WD, Brambilla E, Konrad Müller-Hermelink H, Harris CC (eds.) (2004) Malignant epithelial tumours, In: Pathology and genetics tumours of the lung, pleura, thymus and heart. World Health Organization Classification of Tumours, Springer, Berlin, pp 26-67
21. Wu JT (2002) C-erbB2 oncoprotein and its soluble ectodomain: a new potential tumor marker for prognosis early detection and monitoring patients undergoing Herceptin treatment. Clin Chim Acta 322:11-19
22. Wu JT, Astill ME, Gagon SD, Bryson L (1995) Measurement of c-erbB-2 proteins in sera from patients with carcinomas and in breast tumor tissue cytosols: correlation with serum tumor markers and membrane-bound oncoprotein. J Clin Lab Anal 9:151-165
23. Xu W, Marcu M, Yuan X, Mimnaugh E, Patterson C, Neckers L (2002) Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc Natl Acad Sci USA 99:12847-12852
24. Zhou P, Fernandes N, Dodge IL, Reddi AL, Rao N, Safran H, DiPetrillo TA, Wazer DE, Band V, Band H (2003) ErbB2 degradation mediated by the co-chaperone protein CHIP. J Biol Chem 278:13829-13837